Several other compounds targeting the CCR2/CCL2 and/or CCR5/CCL5 systems will likely be evaluated in fribrotic-NASH patients, either alone or combined with other drugs. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.